Female Reproductive System Squamous Cell Carcinoma

Observed

→ investigated in trials for

Paclitaxelsmall molecule

12 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Bevacizumabmonoclonal antibody

7 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Carboplatinsmall molecule

5 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Atezolizumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cetuximabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Gemcitabinesmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Ipilimumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nimotuzumabmonoclonal antibody

3 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nivolumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pembrolizumabmonoclonal antibody

3 trials (3 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Topotecansmall molecule

3 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Aldesleukinother

2 trials (2 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Avelumabmonoclonal antibody

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Docetaxelsmall molecule

2 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Filgrastimother

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nab-paclitaxel

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Pegfilgrastimother

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Veliparibsmall molecule

2 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Buparlisibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Cyclophosphamidesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Dasatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Doxorubicinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Durvalumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Erlotinib Hydrochloridesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fludarabinesmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Fluorouracilsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Futibatinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Imiquimodsmall molecule

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Nintedanibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Niraparibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Oxaliplatinsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Porcupine Inhibitor WNT974

→ investigated in trials for

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Rigosertibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Sunitinibsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Talimogene Laherparepvecgene therapy

1 trials (1 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Temsirolimussmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Tremelimumabmonoclonal antibody

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Valproic Acidsmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

→ investigated in trials for

Vinorelbinesmall molecule

1 trials (0 active) · roll-up of the cancer and its descendants

—

Observed

Female Reproductive System Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 107show all (up to 200)
→ studied in	NCT07061977Phase 3 · recruiting Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07848243Phase 2 · recruiting Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ALIAS · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07147361active not recruiting Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07217171Phase 1 · recruiting A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Vulvar Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03074513Phase 2 · active not recruiting Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 107 trials mapped (35 active)	—	—	Human Papillomavirus-Related Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804966Phase 2 · not yet recruiting Sac-TMT in Vaginal and Vulvar Cancers · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Vaginal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07602842Phase 1/Phase 2 · recruiting A Study of IDP-001 in Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07796672recruiting Feasibility Study of Blood Biomarker Identification in Cervical Cancer · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02466971Phase 3 · active not recruiting Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Vaginal Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05827614Phase 1 · terminated Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped CURATED_BROADER · 107 trials mapped (35 active)	—	—	Cervical Squamous Cell Carcinoma	1	Observed	clinicaltrials	graph →

Female Reproductive System Squamous Cell Carcinoma studied in …STUDIED_INderived10 of 107show all (up to 200)

→ studied in

NCT07061977Phase 3 · recruiting

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

→ studied in

NCT07848243Phase 2 · recruiting

Clinical Investigator-Initiated Trial (IIT) of PD-L1-Targeted Radionuclide Probes · condition mapped ALIAS · 107 trials mapped (35 active)

—

Observed

→ studied in

NCT07147361active not recruiting

Predictive Biomarkers for PD-1 Inhibitor Response in Squamous Cell Carcinoma · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

Vulvar Squamous Cell Carcinoma

→ studied in

NCT07217171Phase 1 · recruiting

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

Human Papillomavirus-Related Cervical Squamous Cell Carcinoma

→ studied in

NCT03074513Phase 2 · active not recruiting

Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors · condition mapped ONTOLOGY_EXACT · 107 trials mapped (35 active)

—

Observed

Vaginal Squamous Cell Carcinoma

→ studied in

NCT07804966Phase 2 · not yet recruiting

Sac-TMT in Vaginal and Vulvar Cancers · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

→ studied in

NCT07602842Phase 1/Phase 2 · recruiting

A Study of IDP-001 in Advanced or Metastatic Solid Tumors · condition mapped ALIAS · 107 trials mapped (35 active)

—

Observed

→ studied in

NCT07796672recruiting

Feasibility Study of Blood Biomarker Identification in Cervical Cancer · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

Vaginal Squamous Cell Carcinoma

→ studied in

NCT02466971Phase 3 · active not recruiting

Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) During Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed

→ studied in

NCT05827614Phase 1 · terminated

Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications · condition mapped CURATED_BROADER · 107 trials mapped (35 active)

—

Observed